These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26991517)

  • 61. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
    Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
    Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes.
    Christensen M; Andersson K; Dalén P; Mirghani RA; Muirhead GJ; Nordmark A; Tybring G; Wahlberg A; Yaşar U; Bertilsson L
    Clin Pharmacol Ther; 2003 Jun; 73(6):517-28. PubMed ID: 12811361
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator.
    Williams D; Tao X; Zhu L; Stonier M; Lutz JD; Masson E; Zhang S; Ganguly B; Tzogas Z; Lubin S; Murthy B
    Br J Clin Pharmacol; 2017 Feb; 83(2):370-380. PubMed ID: 27552251
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Simultaneous and comprehensive in vivo analysis of cytochrome P450 activity by using a cocktail approach in rats.
    Uchida S; Tanaka S; Namiki N
    Biopharm Drug Dispos; 2014 May; 35(4):228-36. PubMed ID: 24395703
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of commercial Rhodiola rosea on CYP enzyme activity in humans.
    Thu OK; Spigset O; Nilsen OG; Hellum B
    Eur J Clin Pharmacol; 2016 Mar; 72(3):295-300. PubMed ID: 26613955
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
    Ou YC; Tang Z; Novotny W; Tawashi M; Li TK; Coleman HA; Sahasranaman S
    Br J Clin Pharmacol; 2021 Jul; 87(7):2926-2936. PubMed ID: 33336408
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Ghosh A; Pu J; Carayannopoulos LN; Li Y
    J Clin Pharmacol; 2024 Aug; 64(8):984-992. PubMed ID: 38563070
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.
    Donzelli M; Derungs A; Serratore MG; Noppen C; Nezic L; Krähenbühl S; Haschke M
    Clin Pharmacokinet; 2014 Mar; 53(3):271-282. PubMed ID: 24218006
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Repeated administration of berberine inhibits cytochromes P450 in humans.
    Guo Y; Chen Y; Tan ZR; Klaassen CD; Zhou HH
    Eur J Clin Pharmacol; 2012 Feb; 68(2):213-7. PubMed ID: 21870106
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.
    Li H; Canet MJ; Clarke JD; Billheimer D; Xanthakos SA; Lavine JE; Erickson RP; Cherrington NJ
    Drug Metab Dispos; 2017 Dec; 45(12):1317-1325. PubMed ID: 28986475
    [TBL] [Abstract][Full Text] [Related]  

  • 72. In vivo effect of clarithromycin on multiple cytochrome P450s.
    Bruce MA; Hall SD; Haehner-Daniels BD; Gorski JC
    Drug Metab Dispos; 2001 Jul; 29(7):1023-8. PubMed ID: 11408369
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phenotype-Genotype Correlation Applying a Cocktail Approach and an Exome Chip Analysis Reveals Further Variants Contributing to Variation of Drug Metabolism.
    Böhm R; Bruckmueller H; Oswald S; Hübenthal M; Kaehler M; Ehmke L; Höcker J; Siegmund W; Franke A; Cascorbi I
    Clin Pharmacol Ther; 2024 Jul; 116(1):204-216. PubMed ID: 38637968
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
    Miura M; Tanaka S; Uchida S; Kamiya C; Katayama N; Hakamata A; Odagiri K; Inui N; Kawakami J; Watanabe H; Namiki N
    Biol Pharm Bull; 2021; 44(6):762-770. PubMed ID: 34078808
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of colchicine on rat hepatic cytochrome P450 enzymes by cocktail probe drugs.
    Xu BB; Xu ZS; Zheng SL; Tang CR
    Pharmazie; 2014 Jan; 69(1):43-7. PubMed ID: 24601222
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
    Sathe AG; Othman AA; Mohamed MF
    J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Population PK-PD analyses of CD25 occupancy, CD56
    Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
    Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
    Jiang X; Zhuang Y; Xu Z; Wang W; Zhou H
    AAPS J; 2016 May; 18(3):767-76. PubMed ID: 26961818
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects.
    Murase K; Lee L; Ma J; Barrett R; Thoolen M
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1823-1831. PubMed ID: 36166059
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human.
    Grangeon A; Gravel S; Gaudette F; Turgeon J; Michaud V
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jan; 1040():144-158. PubMed ID: 27978469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.